Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies

Plaimauer, B; Kremer Hovinga, J A; Juno, C; Wolfsegger, M J; Skalicky, S; Schmidt, M; Grillberger, L; Hasslacher, M; Knöbl, P; Ehrlich, H; Scheiflinger, F (2011). Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies. Journal of thrombosis and haemostasis, 9(5), pp. 936-44. Oxford: Wiley-Blackwell 10.1111/j.1538-7836.2011.04224.x

Full text not available from this repository. (Request a copy)

Severe deficiency of the von Willebrand factor (VWF)-cleaving protease ADAMTS13 as observed in acquired thrombotic thrombocytopenic purpura (TTP) is caused by inhibitory and non-inhibitory autoantibodies directed against the protease. Current treatment with plasma exchange is considered to remove circulating antibodies and to concurrently replenish the deficient enzyme.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Haematology and Central Haematological Laboratory

UniBE Contributor:

Kremer Hovinga, Johanna Anna

ISSN:

1538-7836

Publisher:

Wiley-Blackwell

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:18

Last Modified:

16 Jul 2018 14:13

Publisher DOI:

10.1111/j.1538-7836.2011.04224.x

PubMed ID:

21294825

Web of Science ID:

000290340800007

URI:

https://boris.unibe.ch/id/eprint/5846 (FactScience: 210699)

Actions (login required)

Edit item Edit item
Provide Feedback